MRX Stock Analysis: Marex Ordinary Shares | NASDAQ
Capital Markets | NASDAQ, USA | Market Cap: 4.615m USD | 12M Return: 105.4% | BMG5T40M1045 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 42.8M
Qual. Beats: 3
Rev. Trend: 92.5%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Seasonality 2.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Marex Group plc is a London-based financial services platform company listed on NASDAQ under the ticker MRX, providing liquidity, market access, and infrastructure services across commodity and financial markets in the UK, US, and internationally. Founded in 2005 and IPOd in 2024, the company operates through four segments: Clearing, Agency and Execution, Market Making, and Hedging and Investment Solutions.
Its service offerings span execution and clearing across metals, agricultural products, energy, fixed income, financial securities, digital assets, and equity futures and options. Marex also provides liquidity in OTC energy markets, market data and analytics, energy market services, and OTC hedging and derivatives solutions. The structured notes business enables investors to build products across commodities, equities, FX, and fixed income for distribution to private banks, asset managers, pension funds, and corporates.
The company supports its operations with proprietary technology platforms, including Neon (a trading, risk, and data platform) and Agile (a commodity broking platform). As a mid-cap financial services firm, Marex sits within the investment banking and brokerage sub-industry, a sector that benefits from increased market volatility and client demand for hedging and execution services.
- Commodity volatility drives Market Making and Execution revenue
- Structured notes growth lifts Hedging and Investment Solutions margins
- Fed rate cuts pressure net interest margins on client balances
| Net Income: 684.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.11 > 1.0 |
| NWC/Revenue: 240.3% < 20% (prev 134.8%; Δ 105.5% < -1%) |
| CFO/TA 0.02 > 3% & CFO 667.5m > Net Income 684.8m |
| Net Debt (-935.2m) to EBITDA (2.75b): -0.34 < 3 |
| Current Ratio: 3.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (75.6m) vs 12m ago 5.49% < -2% |
| Gross Margin: 86.85% > 18% (prev 42.46%; Δ 44.40% > 0.5%) |
| Asset Turnover: 19.04% > 50% (prev 12.54%; Δ 6.50% > 0%) |
| Interest Coverage Ratio: 3.57 > 6 (EBIT TTM 2.72b / Interest Expense TTM 760.2m) |
| A: 0.40 (Total Current Assets 24.5b - Total Current Liabilities 7.75b) / Total Assets 42.1b |
| B: 0.03 (Retained Earnings 1.20b / Total Assets 42.1b) |
| C: 0.07 (EBIT TTM 2.72b / Avg Total Assets 36.7b) |
| D: 0.05 (Book Value of Equity 1.87b / Total Liabilities 40.3b) |
| Altman-Z'' = 3.25 = A |
As of August 22, 2026, the stock is trading at USD 72.99 with a total of 486,449 shares traded. Over the past week, the price has changed by +2.72%, over one month by +12.92%, over three months by +34.05% and over the past year by +105.38%.
Current recommended Stop Loss: 64.30 (which is 11.9% or 2.5 ATR below the current price).
Marex Ordinary Shares has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy MRX.
- StrongBuy: 3
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 79.9 | 9.4% |
P/E Trailing = 14.2602
P/E Forward = 8.7642
P/S = 1.2238
P/B = 2.6995
Revenue TTM = 6.98b USD
EBIT TTM = 2.72b USD
EBITDA TTM = 2.75b USD
Long Term Debt = 2.33b USD (from longTermDebt, last fiscal year)
Short Term Debt = 7.82b USD (from shortTermDebt, last fiscal year)
Debt = 2.92b USD (from shortLongTermDebtTotal, last quarter) + Leases 94.8m
Net Debt = -935.2m USD (calculated: Debt 2.92b - CCE 3.85b)
Enterprise Value = 3.68b USD (4.62b + Debt 2.92b - CCE 3.85b)
Interest Coverage Ratio = 3.57 (Ebit TTM 2.72b / Interest Expense TTM 760.2m)
EV/FCF = 5.62x (Enterprise Value 3.68b / FCF TTM 654.4m)
FCF Yield = 17.78% (FCF TTM 654.4m / Enterprise Value 3.68b)
FCF Margin = 9.38% (FCF TTM 654.4m / Revenue TTM 6.98b)
Net Margin = 9.81% (Net Income TTM 684.8m / Revenue TTM 6.98b)
Gross Margin = 86.85% ((Revenue TTM 6.98b - Cost of Revenue TTM 917.7m) / Revenue TTM)
Gross Margin QoQ = none% (prev 36.59%)
Tobins Q-Ratio = 0.09 (Enterprise Value 3.68b / Total Assets 42.1b)
Interest Expense / Debt = 26.07% (Interest Expense 760.2m / Debt 2.92b)
Taxrate = 24.61% (75.8m / 308.0m)
NOPAT = 2.05b (EBIT 2.72b * (1 - 24.61%))
Current Ratio = 3.16 (Total Current Assets 24.5b / Total Current Liabilities 7.75b)
Debt / Equity = 1.56 (Debt 2.92b / totalStockholderEquity, last quarter 1.87b)
Debt / EBITDA = -0.34 (Net Debt -935.2m / EBITDA 2.75b)
Debt / FCF = -1.43 (Net Debt -935.2m / FCF TTM 654.4m)
Total Stockholder Equity = 1.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.87% (Net Income 684.8m / Total Assets 42.1b)
RoE = 48.37% (Net Income TTM 684.8m / Total Stockholder Equity 1.42b)
RoCE = 72.55% (EBIT 2.72b / Capital Employed (Equity 1.42b + L.T.Debt 2.33b))
RoIC = 4.89% (NOPAT 2.05b / Invested Capital 41.8b)
WACC = 12.84% (E(4.62b)/V(7.53b) * Re(8.53%) + D(2.92b)/V(7.53b) * Rd(26.07%) * (1-Tc(0.25)))
Discount Rate = 8.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -2.49 | Cagr: 2.97%
[DCF] Terminal Value 58.34% ; FCFF base≈850.1m ; Y1≈745.5m ; Y5≈602.3m
[DCF] Fair Price = 90.81 (EV 5.60b - Net Debt -935.2m = Equity 6.53b / Shares 71.9m; r=12.84% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.70 | # QB: 3
Revenue Correlation: 92.51 | Revenue CAGR: 41.73% | SUE: 2.07 | # QB: 3
EPS current Quarter (2026-09-30): EPS=1.50 | Chg30d=+22.09% | Revisions=+44% | Analysts=6
EPS current Year (2026-12-31): EPS=6.13 | Chg30d=+18.74% | Revisions=+50% | GrowthEPS=+53.7% | GrowthRev=+36.4%
EPS next Year (2027-12-31): EPS=6.39 | Chg30d=+10.81% | Revisions=+70% | GrowthEPS=+4.2% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: +70% (up=18, down=2)